When it comes to cutting-edge science that will redefine how we live and work in coming years, there's no shortage of fascinating breakthroughs.
Every week brings dozens of new developments covering everything from bionic eyes to drones the size of humming birds.
Trouble is, very few offer actual opportunities to make money right now, today.
But there is one big-cap juggernaut that provides stock profits to its shareholders while it's busy inventing the tech of the future. And it isn't satisfied pigeon-holed into one specific sector but has its sights set on so many diverse industries (or tech that will affect numerous industries) it's like buying a stock that's an exchange-traded fund (ETF).
Unlike many tech leaders, it isn't sitting on its laurels and market dominance. It's actively looking into cutting-edge sectors to advance its brand. What's more it's product pipeline is blazingly fast and efficient.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.